---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-264162"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T08:46:25.112143+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa raises $25M via pre-funded warrant offering at $2.4999 per share

## Summary
- Gross proceeds ~$25M from sale of pre-funded warrants to purchase 10,000,400 shares.
- Offering price $2.4999 per warrant = Oct 25 closing price less $0.0001 exercise price.
- Warrants immediately exercisable at $0.0001; 4.99% beneficial ownership cap (up to 19.99% at holder's election).
- Net proceeds to advance pipeline: MRT-2359, MRT-6160 (VAV1 MGD), and NEK7 program.
- Closing expected on or about Oct 30, 2023, subject to customary conditions.

## SEC filing metadata
- accession: 0001193125-23-264162
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000119312523264162/0001193125-23-264162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000119312523264162/d512767d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-264162
- JSON: https://secwatch.observer/filing/0001193125-23-264162.json
- Plain text: https://secwatch.observer/filing/0001193125-23-264162.txt

## Key facts
- Material Agreements
  Monte Rosa Therapeutics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $25.0 million (effective 2023-10-26).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $25.0 million
  - Effective: 2023-10-26
  source text: Monte Rosa Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors relating to the issuance and sale of pre-funded warrants to purchase 10,000,400 shares of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000119312523264162/0001193125-23-264162-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.